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Abstract
Background: Safety for diabetic patients means providing the most suitable treatment for each type of diabetic in
order to improve monitoring and to prevent the adverse effects of drugs and complications arising from the
disease. The aim of this study is to analyze the effect of imparting educational interventions to health professionals
regarding the safety of patients with Diabetes Mellitus (DM).
Methods: Design: A cluster randomized trial with a control group.
Setting and sample: The study analyzed ten primary healthcare centres (PHC) covering approximately 150,000
inhabitants. Two groups of 5 PHC were selected on the basis of their geographic location (urban, semi-urban and
rural), their socio-economic status and the size of their PHC, The interventions and control groups were assigned at
random. The study uses computerized patient records to individually assess subjects aged 45 to 75 diagnosed with
type 1 and type 2 DM, who met the inclusion conditions and who had the variables of particular interest to the
study.
Trial: The educational interventions consisted of a standardized teaching course aimed at doctors and nurses. The
course lasted 6 hours and was split into three 2-hour blocks with subsequent monthly refresher courses.
Measurement: For the health professionals, the study used the Diabetes Attitude Scale (DAS-3) to assess their
attitudes and motivation when monitoring diabetes. For the patients, the study assessed factors related to their
degree of control over the disease at onset, 6, 12 and 24 months.
Main variables: levels of HbA1c.
Analysis: The study analyzed the effect of the educational interventions both on the attitudes and motivations of
health professionals and on the degree of control over the diabetes in both groups.
Discussion: Imparting educational interventions to health professionals would improve the monitoring of diabetic
patients. The most effective model involves imparting the course to both doctors and nurses. However, these
models have not been tested on our Spanish population within the framework of primary healthcare.
Trial registration: ClinicalTrials.gov: NCT01087541
Background
Safety for diabetic patients refers both to the way in
which they are handled and to the suitability and phar-
macological safety of the treatment they are given. This
is not just a financial issue but a broader concept which
means providing suitable healthcare that is in line with
the latest findings [1].
We have known for some time that getting diabetic
patients to perform repetitive self-measurements of
capillary glycemia does not improve the way in which
they are monitored [2,3]. Therapeutic educational mea-
sures are better. Although they seem more complex,
their performance is more optimal [4-6].
A broad consensus is lacking on several issues con-
cerning the treatment of diabetic patients. These issues
include the systematic use of anti-aggregant treatment
[7], the use of statins [8], the use of ACE inhibitors or
ARB (even when the patient is not hypertensive) [9], the
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any medium, provided the original work is properly cited.need to calculate the cardiovascular risk and the value of
classifying diabetic patients as high-risk. The answers to
all these issues may vary depending on the method used
to resolve them.
According to a recent review of medical errors in dia-
betes, patient follow-up can often include such problems
as drug incompatibilities, contraindications, therapeutic
inertia, a lack of desirable monitoring and the non-detec-
tion or control of other diabetes-associated risk factors.
Some estimates state that there is a 63.2% chance that
these problems will occur over a year (22% for glycemia
monitoring, 58% for lipid monitoring and 10% for inap-
propriate prescription) [10]. Clinical practice guides have
attempted to partially resolve this problem. Each guide
sets out the guaranteed minimum care level and recom-
mends preventive measures or screening. Nonetheless, the
heterogeneous nature of these guides prevents them from
being effectively applied in BHA; that is, they provide
highly homogeneous results that conceal any significant
differences at either individual or group level [11-13].
Over the last few years we have seen many advances
in the treatment and handling of diabetic patients. Some
of these treatments use rosiglitazone or pioglitazone;
however, their adoption has been limited by the
increased risk of heart failure and ischemic coronary
events associated with the use of rosiglitazone, and the
increased risk of bone fractures in women treated with
rosiglitazone or pioglitazone [14,15]. Other studies have
tried to develop safer treatments such as insulin analogs
[16]. Although the principal obstacle to improving new
treatments is often financial, sometimes it can be thera-
peutic inertia, which is very difficult to resolve [17].
We should point out that in our evidence-based
assessment of therapeutic alternatives we have consid-
ered the points recommended by the World Health
Organization (WHO) regarding essential drugs. These
points refer to the efficacy, safety, financial cost and
ease of administration of a given drug. Examples of
these points can be found in the following list of mea-
sures relating to diabetic patient safety: 1) creating con-
sensual diagnostic criteria and defining abnormal
baseline glycemia and glucose intolerance as prediabetic
conditions; 2) not marketing a glitazone (troglitazone) in
Spain because of serious liver problems observed in the
United States [18,19]; 3) describing potentially hazar-
dous interactions between antidiabetic drugs or between
antidiabetics and other drugs in polymedicated patients;
4) reaffirming the efficacy of programs for weight loss
and physical exercise as a means of prevention [20,21];
5) recommending anti-aggregation treatment for high-
risk diabetics; 6) providing insulins and oral antidia-
betics with a lower risk of hypoglycemia; 7) improving
metabolic monitoring (glycosylated hemoglobin); 8) dis-
seminating screening and education programs regarding
complications of Diabetes Mellitus (DM) such as dia-
betic foot, ECG, Doppler; 9) setting up a non-mydriatic
camera program to detect diabetic retinopathy; 10) pro-
viding lifelong diabetology training for the family doctor;
11) monitoring certain parameters of the diabetic
patient by means of a computerized program for mana-
ging clinical histories within the field of primary care;
12) setting up an oral health program in diabetics; 13)
carrying out diabetes prevention programs.
Given the somewhat uncertain situation regarding the
monitoring and follow-up of diabetic patients, is reason-
able to think that whether the monitoring of diabetes
patients improves in the medium-term when the doctors
and nurses who care for them are provided specific life-
long training which prioritizes their professional
approach to these patients [22,23]. Therefore, with the
aim of improving the safety of diabetic patients, we
would like to know how educational interventions affect
the way in which health professionals monitor diabetic
patients.
Methods
Design and study period
A cluster randomized trial controlled was carried out in
primary healthcare centres (PHC). Ten PHC were dis-
tributed randomly into two groups: five PHC in the
intervention group and five PHC in the control group.
The study ran from November 2007 to December
2009. The intervention was aimed at health profes-
sionals lasted six months. At the start of the interven-
tion period a test was performed on the health
professionals’ attitudes and motivations towards dia-
betics; a re-test was performed at the end of this period.
During the next 5 months, monthly refresher tests were
given. After this, the effect of the intervention given to
health professionals working with patients with DM was
estimated at baseline to 6, 12 and 24 months after the
intervention. During the inclusion period, the baseline
d a t ao ft h ed i a b e t i cp a t i e n t sw e r eo b t a i n e df r o mt h e1 0
PHC (Figure 1).
Study population
HbA1c was used as the principal variable for calculating
the sample size. On the basis of previous studies, redu-
cing HbA1c by 0.25% over 1 year was assumed to be
clinically significant. Therefore, on the basis of an alpha
risk of 0.05 and a beta risk of 0.10 in a bilateral compar-
ison, 337 subjects were needed for each group. In order
to compute the effect of the design, the size of the sam-
ple was multiplied by 2 (n = 674), and 5% was added for
possible recording errors, and 10% for losses during
patient follow-up. The final sample was 775 subjects in
each group.
The population was selected in 3 phases:
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The study was performed in a geographic area covering
32 PHC (primary healthcare centers) of the Catalan
Health Institute from Tarragona-Reus, Catalonia, Spain.
Ten PHC with different geographic locations (urban,
semi-urban and rural) and socio-economic statuses
(high-medium and medium-low) were selected, repre-
senting approximately 150,000 inhabitants. According to
our own data, there were 7,350 subjects in the 10 PHC
with type 1 and type 2 DM (DM1, DM2) and aged 45-
75. Consequently, we had a sufficiently large database to
eliminate subjects who did not comply with the exclu-
sion criteria.
Phase 2: Participation of professionals
All health professionals from the 5 PHC of the interven-
tion group were informed about the study and of the
possibility of participating in a voluntary manner. If they
accepted they had to sign an informed consent form.
Joint participation of the doctor and nurse team was the
only criteria for selection.
Phase 3: Selection of patients with DM
All the diabetic patients that were seen by professionals
from the 10 PHC were included in the study. The inclu-
sion criteria were being diagnosed with DM1 and DM2
in the primary-care patient computer records, and being
aged 45-75. The exclusion criteria were: not having the
study variables, suffering from a serious terminal disease
or being monitored exclusively by a specialist (endocri-
nologist or other).
Allocation of study groups
To ensure that the intervention group and the control
group were comparable, they were paired with another
center with similar characteristics in terms of area
(urban/semiurban/rural), socio-economic status, cultural
status and size of the PHC. Pairs were distributed into 2
groups and then randomly designated as the interven-
tion group and the control group.
Intervention
The intervention consisted of imparting a series of
teaching courses on DM [24] at each of the centers of
the intervention group. Each course involved 6 teaching
hours split into 3 blocks of 2 hours, in which both doc-
tors and nurses participated. The content of the sessions
was standardized and taught by 3 primary care doctors
and a clinical pharmacologist, each person imparting a
particular section of each session. A primary care doctor
presented the project, the other two doctors presented
the remaining part of the course and the workshops,
and the clinical pharmacologist presented the section on
drug safety.
The study was standardized into the following 3
blocks. On the first day the project was presented and
the participants were asked to fill in the questionnaire
on their attitudes and motivations regarding diabetes,
the Diabetes Attitude Scale (DAS-3). The most impor-
tant adverse effects and pharmacological interactions
were also explained. On the second day the workshop
on therapeutic education was held to explain concepts
regarding adult education prioritize activities and hold
experience and reflection workshops. On the third day
the current pharmacological treatment of diabetes
were examined and clinical practice guides for dia-
betes were reviewed. At the end of the sessions, parti-
cipants were asked to fill in questionnaire DAS-3
again.
The main aim of the educational sessions was to
encourage the participants to reflect on the aspects of
communication and learning that emerged during each
workshop. These involved awareness sessions in which,
professionals did tactile discrimination, verbal and non-
verbal communication or trust building exercises.
The pharmacological warnings section reported the
safety profile of the drugs used in diabetics (oral antidia-
betics and insulin), thus allowing us to identify possible
adverse effects and interactions.
Trial group
Control Group 
Primary 
care centers
1 month 2-6 months
Collection of 
baseline 
diabetic data 
inclusion
Intervention
DAS-
3Test 
DAS-3
Re-test
Non intervention
Reinforcements
First data 
collation
6-18
months
Second data 
collation
Figure 1 Study design.
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reminders were issued both in paper and electronic for-
mat to all the professionals participating in the interven-
tion group. This material included: 5 information
bulletins (pharmacological warnings, criteria for moni-
toring DM, periodic trials to be performed, dietary and
physical exercise advice) and suggestions from the
DESG group (Diabetes Education Study Group).
A record of each patient’s hypoglycemic status was
given to the professionals. This included: the patient’s
sex, the number of years he/she had DM (divided into
three groups: less than 5 years, 5 to 10 years and
more than 10 years), the type of treatment usually
received, and confirmation or not of the presence of
hypoglycemia and its possible causes. A record of each
patient’s admissions to hospital due to diabetes related
conditions (including hypoglycemia, non-ketotic
hyperosmolar condition, ketoacidosis, amputation,
ischemic cardiopathy, diabetic neuropathy, etc) was
also given.
Someone was available throughout resolve any queries
from the professionals.
During this educational phase various aspects were
considered. On the one hand, we looked at the ability of
all health members to access training sessions and the
current limited recommendations regarding the type of
education and the frequency of the sessions they should
have. It seems that to have the maximum effect, sessions
should follow certain principles of good clinical practice:
- Courses should follow an adult education
methodology.
- Education should be provided by a multidisciplinary
team with group leadership skills.
- Sessions should be made accessible to the majority
of professionals by taking into account the professionals’
availability.
- Educational programs should use several techniques
to promote active learning, to adapt to the reality of
Health-Primary Care, to take into account local differ-
ences and to ensure they can be integrated into normal
clinical practice.
Control group
The management of each center was informed about the
study. Professionals from these centers were able to con-
tinue their normal clinical practice and were able to
carry out their own training following their own criteria
and using guides or courses not included within the
intervention.
Measurements
Two sets of results are monitored separately: One for
the effect of the intervention on the heath professionals
and the other on the diabetic patients.
To assess the effect of the intervention on health pro-
fessionals the DAS-3 questionnaire is used, which was
validated in Spain by one of the members of the study
group (both in Spanish and Catalan) [25,26]. The DAS-3
is a questionnaire regarding professionals’ attitudes and
knowledge towards of diabetics. It comprises 33 ques-
tions covering various aspects such as the need for spe-
cial training, the perception of the seriousness of DM,
the assessment of strict monitoring, the assessment of
the psychosocial impact of DM, and patient autonomy.
The questionnaire was filled in by professionals at the
start and end of the month-long course.
To follow-up the diabetic patients, several parameters
were defined which could be monitored using the
patients’ clinical histories from their Primary Care com-
puter records. These parameters were monitored at the
start of the intervention and at 6, 12 and 24 months
after the intervention on health professionals.
The control items monitored are: HbA1c, cardiovascu-
lar risk score, ECG, aspirin or other anti-aggregates
treatment, blood pressure, LDL-cholesterol, tobacco
habit, body mass index.
The optimal systolic and diastolic blood pressure
values are less than 130 and 85 mmHg respectively,
according to the guide from the Catalan Health
Institute.
The optimal LDL-cholesterol values are less than 100
mg/dL according to the American Diabetes Association
guide [24].
The control items did not include the number of visits
made by diabetics to the doctor’s because the reasons
for such visits can vary greatly. Consumption of strips
for selfcontrol was also not taken into account because
this does not correlated with degrees of control or with
cardiovascular complications when the follow-up period
is short-term.
Statistical methods
The variables collated for the professional and patient
are reported as mean and standard deviations and as
percentages.
A chi-squared test, t student Fisher’s and analysis of
variance were used to compare means and proportions.
Kolmogorov-Smirnov tests were used to verify the
hypothesis regarding the normal distribution of quanti-
tative variables. In the case of non-compliance with test
conditions, non-parametric tests were applied.
The results of the DAS-3 test, before and after the
educational intervention, were compared between the
intervention and control group. The differences between
doctors and nurses were also estimated.
The results from variables recorded in the patient were
compared in both groups before the educational inter-
vention to ensure their comparability. The results before
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pared for both the intervention and the control group.
The effects of the educational intervention were mea-
sured by adjusting with other variables related to the
monitoring of DM, such as age, sex, BMI, the socio-eco-
nomic status of the PHC, and any other characteristic
depending on the model used. Consequently, the multi-
variate statistical methods of multiple linear regression
and logistical regression were used. Conditions for
applying models were verified mainly by analyzing resi-
duals. During the first phase, a theoretical model includ-
ing all the variables was made. During the second phase,
automatic selection using the backward and forward
method was carried out to obtain more reduced models.
In all cases the level of significance was set at p <
0.05.
Version 17.0 of the statistical programs package SPSS/
PC for Windows was used to analyze data.
Ethical Aspects
The study protocol was evaluated and approved by the
Ethics Committee of Assistance (CEA) of the Institut
d’Investigació en Atenció Primària, Jordi Gol (IDIAP
Jordi Gol). Informed consent was obtained from the
health professionals in both the trial and control groups.
Forecast execution dates
- Protocol design: October - November 2007.
- Presentation of the study to health centers: Decem-
ber 2007
- Intervention period: January 2008
- Period for sending reinforcements: February - June
2008
- Initial data collation: July-August 2008
- Subsequent data collations: July-August 2009
- Publication of final results: December 2010
Discussion
There is currently no broad consensus regarding the
treatment and follow-up of diabetic patients. Some
researchers have highlighted that a high percentage of
health professionals find it difficult to follow up diabetic
patients [10]. Although recommendations have
attempted to resolve these difficulties, it seems that gen-
eral monitoring of diabetic patients continues to be
defective [11-13]. Furthermore, recent medical advances
in treating diabetic patients have often not been trans-
lated into recommendations for providing primary care
treatment and monitoring [17]. Therefore, it is consid-
ered important to provide specific lifelong and struc-
tured training to health professionals with the purpose
of improving the medium-term monitoring of diabetic
patients in primary care centers.
The study was designed to randomly select a limited
number of basic health areas concentrated in a geo-
g r a p h i ca r e aa n dw i t hs i m i l a r socio-demographic and
cultural characteristics, thus guaranteeing the homoge-
neity of the patients in each group.
In addition, the socio-demographic and cultural char-
acteristics of our geographic area correspond to mean
levels in other basic health areas of industrialized coun-
tries, which also means these results can be applied to
similar fields.
The training methodology performed in this study
consisted of short educational sessions, with periodic
reinforcements, which represents a new method when
compared with the traditional methods used in differ-
ent primary care centers. This is because it prioritizes
interactivity of all professionals through practical
workshops. The method also prioritizes the group
knowledge rather than the individual knowledge.
Another important point is to use the questionnaire
on attitudes and knowledge about diabetes and the
analysis within the group to determine the weakest
points perceived by professionals so that these can be
resolved.
This study has been disseminated electronically
b e c a u s ei ti sam o r ee n v i r o n m e n t a l l yf r i e n d l yf o r mo f
giving feedback than using paper. New technologies
(video, music and photography) were also used to
improve communication.
To summarize, the SEGUDIAB program can be
considered an useful method for improving the care of
diabetic patients because it provides tools and knowl-
edge for modifying the attitudes of health professionals.
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